The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
World
  • SCMP
  • Asia
Wed, May 25, 2022 | 07:52
Europe & Africa
Norway officially excludes AstraZeneca from vaccination campaign
Posted : 2021-05-13 10:50
Updated : 2021-05-13 10:50
Print Preview
Font Size Up
Font Size Down
In this file photo taken on March 31, doses of AstraZeneca's vaccine against the coronavirus are pictured at a doctor's office in Deisenhofen, southern Germany. Norway will not resume use of the COVID-19 vaccine made by AstraZeneca, Prime Minister Erna Solberg said Wednesday. AFP-Yonhap
In this file photo taken on March 31, doses of AstraZeneca's vaccine against the coronavirus are pictured at a doctor's office in Deisenhofen, southern Germany. Norway will not resume use of the COVID-19 vaccine made by AstraZeneca, Prime Minister Erna Solberg said Wednesday. AFP-Yonhap

Norway will not resume use of the COVID-19 vaccine made by AstraZeneca, and a decision on whether to include Johnson & Johnson (JJ) shots in its mass inoculation scheme remains on hold, Prime Minister Erna Solberg said on Wednesday.

A government-appointed commission had recommended that both vaccines be excluded from Norway's program due to the risk of rare but harmful side-effects.

Authorities on March 11 suspended the AstraZeneca rollout after a small number of inoculated people, some of whom later died, were hospitalized for a combination of blood clots, bleeding and a low platelet count.

A study in Denmark and Norway found slightly increased rates of blood clots among people who have had a first dose of AstraZeneca's vaccine, including in the brain, compared with expected rates in the general population.

JJ vaccine has not been used in Norway so far despite European Medicines Agency (EMA) approval.

On May 10, a public panel of medical, legal and other experts said the two vaccines should not be offered as part of the national inoculation scheme, although volunteers should be allowed to take them.

"The government has decided that the AstraZeneca vaccine will not be used in Norway, not even for volunteers," Solberg said.

The government will build a stockpile of JJ shots, primarily as an emergency backup, while AstraZeneca doses will likely be redistributed, either to European Union countries or through the global Covax scheme, Solberg said.

Norway currently uses only vaccines made by Moderna and Pfizer/BioNTech, and expects all adults to be offered at least one dose of either by late July.

One third of Norwegian adults have so far received the first of two doses.

Volunteers keen to speed up their vaccination will be allowed to take the JJ shot, when the guidelines for such use are approved, but AstraZeneca shot will be excluded completely, the health ministry said.

JJ and AstraZeneca were not immediately available for comment. (Reuters)


 
  • 75th Cannes Film Festival
  • Attention needed to end modern-day slavery
  • [INTERVIEW] How brewery waste turned into pizza dough, energy bars at RE:harvest
  • Ex-Gyeryong mayor found dead after losing nomination in local elections
  • Labor union opposes resumption of late-night subway operations
  • Samsung to invest 450 trillion won to cement lead in chip, bio sectors
  • Gov't to ease tax burden that increased during previous administration
  • Mother charged with killing disabled daughter
  • Premier League Golden Boot winner Son Heung-min receives hero's welcome home
  • Japan hosts Quad summit seeking unity on countering China
  • 'GOT7 has not disbanded' 'GOT7 has not disbanded'
  • Hollywood blockbuster sequels poised to hit theaters, streaming platforms Hollywood blockbuster sequels poised to hit theaters, streaming platforms
  • Girl group NiziU to begin 1st Japanese tour Girl group NiziU to begin 1st Japanese tour
  • Actor's short film 'Dark Yellow' nominated for Asia competition at Japan's film festival Actor's short film 'Dark Yellow' nominated for Asia competition at Japan's film festival
  • 'The Roundup' lures 2.5 million moviegoers over weekend 'The Roundup' lures 2.5 million moviegoers over weekend
DARKROOM
  • 75th Cannes Film Festival

    75th Cannes Film Festival

  • People in North Korea trapped in famine and pandemic

    People in North Korea trapped in famine and pandemic

  • 2022 Pulitzer Prize: Bearing witness to history

    2022 Pulitzer Prize: Bearing witness to history

  • Worsening drought puts millions at risk

    Worsening drought puts millions at risk

  • Our children deserve the best

    Our children deserve the best

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group